ATP8B4 | ATPase, class I, type 8B, member 4 | Enzymes Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
ATP9B | ATPase, class II, type 9B | Enzymes Predicted membrane proteins
| | | | | Expressed in all |
ATRAID | All-trans retinoic acid-induced differentiation factor | Predicted membrane proteins
| | | | | Expressed in all |
ATRN | Attractin | Plasma proteins Predicted membrane proteins
| | | | | Expressed in all |
ATRNL1 | Attractin-like 1 | Predicted membrane proteins
| | | | | Tissue enhanced |
AUP1 | Ancient ubiquitous protein 1 | Predicted membrane proteins
| | | | | Expressed in all |
AWAT2 | Acyl-CoA wax alcohol acyltransferase 2 | Enzymes Predicted membrane proteins
| | | | | Not detected |
BAI3 | Brain-specific angiogenesis inhibitor 3 | G-protein coupled receptors Plasma proteins Predicted membrane proteins
| | | | | Tissue enriched |
BAK1 | BCL2-antagonist/killer 1 | Predicted membrane proteins Transporters
| | | | | Expressed in all |
BCAP29 | B-cell receptor-associated protein 29 | Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Expressed in all |
BCL2 | B-cell CLL/lymphoma 2 | Cancer-related genes Disease related genes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted membrane proteins
| | | | | Expressed in all |
BCL2L1 | BCL2-like 1 | Cancer-related genes Mitochondrial proteins Predicted membrane proteins RAS pathway related proteins Transporters
| | | | | Expressed in all |
BCL2L2 | BCL2-like 2 | Cancer-related genes Mitochondrial proteins Predicted membrane proteins Transporters
| | | | | Expressed in all |
BEST1 | Bestrophin 1 | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Mixed |
BEST3 | Bestrophin 3 | Predicted membrane proteins
| | | | | Tissue enhanced |
BFAR | Bifunctional apoptosis regulator | Predicted membrane proteins
| | | | | Expressed in all |
BMPR2 | Bone morphogenetic protein receptor, type II (serine/threonine kinase) | Disease related genes Enzymes Potential drug targets Predicted membrane proteins
| | | | | Mixed |
BRI3 | Brain protein I3 | Predicted membrane proteins
| | | | | Expressed in all |
BSCL2 | Berardinelli-Seip congenital lipodystrophy 2 (seipin) | Disease related genes Predicted membrane proteins
| | | | | Expressed in all |
BTN2A2 | Butyrophilin, subfamily 2, member A2 | Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
BVES | Blood vessel epicardial substance | Predicted membrane proteins
| | | | | Tissue enhanced |
BX649567.1 | Uncharacterized protein | Predicted membrane proteins
| | | | | Not detected |
C10orf111 | Chromosome 10 open reading frame 111 | Predicted membrane proteins
| | | | | Tissue enhanced |
C10orf128 | Chromosome 10 open reading frame 128 | Predicted membrane proteins
| | | | | Mixed |
C10orf129 | Chromosome 10 open reading frame 129 | Enzymes Mitochondrial proteins Predicted membrane proteins
| | | | | Tissue enhanced |
C12orf55 | Chromosome 12 open reading frame 55 | Predicted membrane proteins
| | | | | Tissue enhanced |
C14orf180 | Chromosome 14 open reading frame 180 | Predicted membrane proteins
| | | | | Group enriched |
C16orf58 | Chromosome 16 open reading frame 58 | Predicted membrane proteins
| | | | | Expressed in all |
C17orf62 | Chromosome 17 open reading frame 62 | Predicted membrane proteins
| | | | | Expressed in all |
C1orf101 | Chromosome 1 open reading frame 101 | Predicted membrane proteins
| | | | | Tissue enriched |
C1orf27 | Chromosome 1 open reading frame 27 | Predicted membrane proteins
| | | | | Expressed in all |
C1orf50 | Chromosome 1 open reading frame 50 | Predicted membrane proteins
| | | | | Expressed in all |
C1orf95 | Chromosome 1 open reading frame 95 | Predicted membrane proteins
| | | | | Tissue enhanced |
C20orf141 | Chromosome 20 open reading frame 141 | Predicted membrane proteins
| | | | | Tissue enriched |
C3orf52 | Chromosome 3 open reading frame 52 | Predicted membrane proteins
| | | | | Mixed |
C5orf28 | Chromosome 5 open reading frame 28 | Predicted membrane proteins
| | | | | Expressed in all |
C6orf136 | Chromosome 6 open reading frame 136 | Predicted membrane proteins
| | | | | Expressed in all |
C9orf69 | Chromosome 9 open reading frame 69 | Predicted membrane proteins
| | | | | Expressed in all |
C9orf91 | Chromosome 9 open reading frame 91 | Predicted membrane proteins
| | | | | Expressed in all |
CACFD1 | Calcium channel flower domain containing 1 | Predicted membrane proteins Transporters
| | | | | Expressed in all |
CACNA1A | Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
CACNA2D3 | Calcium channel, voltage-dependent, alpha 2/delta subunit 3 | Predicted membrane proteins Transporters
| | | | | Mixed |
CACNG6 | Calcium channel, voltage-dependent, gamma subunit 6 | Predicted membrane proteins Transporters
| | | | | Group enriched |
CAMLG | Calcium modulating ligand | FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Expressed in all |
CANX | Calnexin | Cancer-related genes Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
CATSPERD | Catsper channel auxiliary subunit delta | Predicted membrane proteins Transporters
| | | | | Group enriched |
CCDC109B | Coiled-coil domain containing 109B | Predicted membrane proteins Transporters
| | | | | Expressed in all |
CCDC51 | Coiled-coil domain containing 51 | Predicted membrane proteins
| | | | | Expressed in all |
CCR10 | Chemokine (C-C motif) receptor 10 | Cancer-related genes G-protein coupled receptors Plasma proteins Predicted membrane proteins
| | | | | Mixed |
CCR2 | Chemokine (C-C motif) receptor 2 | CD markers G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |